The Next Generation of Positron Emission Tomography Radiopharmaceuticals in Oncology

Delbeke, 1999, Oncological applications of FDG PET imaging: brain tumors, colorectal cancer, lymphoma and melanoma, J Nucl Med, 40, 591 Weber, 1999, Relevance of positron emission tomography (PET) in oncology, Strahlenther Onkol, 175, 356, 10.1007/s000660050022 Glaser, 2003, Applications of positron-emitting halogens in PET oncology, Int J Oncol, 22, 253 Dunphy, 2009, Radiopharmaceuticals in preclinical and clinical development for monitoring of therapy with PET, J Nucl Med, 50, 106S, 10.2967/jnumed.108.057281 DeGrado, 2001, Synthesis and evaluation of (18)F-labeled choline analogs as oncologic PET tracers, J Nucl Med, 42, 1805 DeGrado, 2001, Synthesis and evaluation of 18F-labeled choline as an oncologic tracer for positron emission tomography: initial findings in prostate cancer, Cancer Res, 61, 110 Hara, 2001, 18F-fluorocholine: a new oncologic PET tracer, J Nucl Med, 42, 1815 DeGrado, 2002, Pharmacokinetics and radiation dosimetry of 18F-fluorocholine, J Nucl Med, 43, 92 Iwata, 2001, Induction of primer pheromone production by dihydrotestosterone in the male goat, J Vet Med Sci, 63, 347, 10.1292/jvms.63.347 Cimitan, 2006, [18F]fluorocholine PET/CT imaging for the detection of recurrent prostate cancer at PSA relapse: experience in 100 consecutive patients, Eur J Nucl Med Mol Imaging, 33, 1387, 10.1007/s00259-006-0150-2 Kryza, 2008, Fully automated [18F]fluorocholine synthesis in the TracerLab MX FDG Coincidence synthesizer, Nucl Med Biol, 35, 255, 10.1016/j.nucmedbio.2007.11.008 Talbot, 2010, Detection of hepatocellular carcinoma with PET/CT: a prospective comparison of 18F-fluorocholine and 18F-FDG in patients with cirrhosis or chronic liver disease, J Nucl Med, 51, 1699, 10.2967/jnumed.110.075507 Kwee, 2006, Localization of primary prostate cancer with dual-phase 18F-fluorocholine PET, J Nucl Med, 47, 262 Heinisch, 2006, Positron emission tomography/computed tomography with F-18-fluorocholine for restaging of prostate cancer patients: meaningful at PSA < 5 ng/mL?, Mol Imaging Biol, 8, 43, 10.1007/s11307-005-0023-2 Schmid, 2005, Fluorocholine PET/CT in patients with prostate cancer: initial experience, Radiology, 235, 623, 10.1148/radiol.2352040494 Price, 2002, Comparison of [18 F]fluorocholine and [18 F]fluorodeoxyglucose for positron emission tomography of androgen dependent and androgen independent prostate cancer, J Urol, 168, 273, 10.1016/S0022-5347(05)64906-3 Kwee, 2005, Prostate cancer localization with 18fluorine fluorocholine positron emission tomography, J Urol, 173, 252, 10.1097/01.ju.0000142099.80156.85 Beauregard, 2010, Pilot comparison of F-fluorocholine and F-fluorodeoxyglucose PET/CT with conventional imaging in prostate cancer, J Med Imaging Radiat Oncol, 54, 325, 10.1111/j.1754-9485.2010.02178.x Eschmann, 2007, Comparison of 11C-choline-PET/CT and whole body-MRI for staging of prostate cancer, Nuklearmedizin, 46, 161, 10.1160/nukmed-0075 Beheshti, 2009, Prostate cancer: role of SPECT and PET in imaging bone metastases, Semin Nucl Med, 39, 396, 10.1053/j.semnuclmed.2009.05.003 Husarik, 2008, Evaluation of [(18)F]-choline PET/CT for staging and restaging of prostate cancer, Eur J Nucl Med Mol Imaging, 35, 253, 10.1007/s00259-007-0552-9 Enzinger, 2005, Tumefactive demyelinating lesions: conventional and advanced magnetic resonance imaging, Mult Scler, 11, 135, 10.1191/1352458505ms1145oa Law, 2002, Spectroscopic magnetic resonance imaging of a tumefactive demyelinating lesion, Neuroradiology, 44, 986, 10.1007/s00234-002-0872-1 Kwee, 2007, Solitary brain lesions enhancing at MR imaging: evaluation with fluorine 18 fluorocholine PET, Radiology, 244, 557, 10.1148/radiol.2442060898 Liu, 1992, Fluorine-18-labeled androgens: radiochemical synthesis and tissue distribution studies on six fluorine-substituted androgens, potential imaging agents for prostatic cancer, J Nucl Med, 33, 724 Liu, 1992, Synthesis of high affinity fluorine-substituted ligands for the androgen receptor: potential agents for imaging prostatic cancer by positron emission tomography, J Med Chem, 35, 2113, 10.1021/jm00089a024 Mori, 2010, Automated synthesis of 16{beta}-[18F]fluoro-5{alpha}-dihydrotestosterone using a plastic cassette-type FDG synthesizer, J Nucl Med Meeting Abstracts, 51, 1525 Agus, 1999, Prostate cancer cell cycle regulators: response to androgen withdrawal and development of androgen independence, J Natl Cancer Inst, 91, 1869, 10.1093/jnci/91.21.1869 Agus, 1998, Positron emission tomography of a human prostate cancer xenograft: association of changes in deoxyglucose accumulation with other measures of outcome following androgen withdrawal, Cancer Res, 58, 3009 Choe, 1995, Synthesis of 11 beta-[18F]fluoro-5 alpha-dihydrotestosterone and 11 beta-[18F]fluoro-19-nor-5 alpha-dihydrotestosterone: preparation via halofluorination-reduction, receptor binding, and tissue distribution, J Med Chem, 38, 816, 10.1021/jm00005a009 Beattie, 2010, Pharmacokinetic assessment of the uptake of 16beta-18F-fluoro-5alpha-dihydrotestosterone (FDHT) in prostate tumors as measured by PET, J Nucl Med, 51, 183, 10.2967/jnumed.109.066159 Bonasera, 1996, Preclinical evaluation of fluorine-18-labeled androgen receptor ligands in baboons, J Nucl Med, 37, 1009 Larson, 2004, Tumor localization of 16beta-18F-fluoro-5alpha-dihydrotestosterone versus 18F-FDG in patients with progressive, metastatic prostate cancer, J Nucl Med, 45, 366 Dehdashti, 2005, Positron tomographic assessment of androgen receptors in prostatic carcinoma, Eur J Nucl Med Mol Imaging, 32, 344, 10.1007/s00259-005-1764-5 Zanzonico, 2004, PET-based radiation dosimetry in man of 18F-fluorodihydrotestosterone, a new radiotracer for imaging prostate cancer, J Nucl Med, 45, 1966 Haubner, 2001, Noninvasive imaging of alpha(v)beta3 integrin expression using 18F-labeled RGD-containing glycopeptide and positron emission tomography, Cancer Res, 61, 1781 Haubner, 2004, [F-18]Galacto-RGD: synthesis, radiolabeling, metabolic stability, and radiation dose estimates, Bioconjug Chem, 15, 61, 10.1021/bc034170n Li, 2010, Radiopharmaceutical chemistry for positron emission tomography, Adv Drug Deliv Rev, 62, 1031, 10.1016/j.addr.2010.09.007 Cox, 1994, The pharmacology of the integrins, Med Res Rev, 14, 195, 10.1002/med.2610140203 Brooks, 1994, Integrin alpha v beta 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels, Cell, 79, 1157, 10.1016/0092-8674(94)90007-8 Brooks, 1994, Requirement of vascular integrin alpha v beta 3 for angiogenesis, Science, 264, 569, 10.1126/science.7512751 Teti, 2002, The role of the alphaVbeta3 integrin in the development of osteolytic bone metastases: a pharmacological target for alternative therapy?, Calcif Tissue Int, 71, 293, 10.1007/s00223-001-2071-1 Ruoslahti, 1987, New perspectives in cell adhesion: RGD and integrins, Science, 238, 491, 10.1126/science.2821619 Haubner, 1999, Radiolabeled alpha(v)beta3 integrin antagonists: a new class of tracers for tumor targeting, J Nucl Med, 40, 1061 Beer, 2006, PET-based human dosimetry of 18F-galacto-RGD, a new radiotracer for imaging alpha v beta3 expression, J Nucl Med, 47, 763 Beer, 2005, Biodistribution and pharmacokinetics of the alphavbeta3-selective tracer 18F-galacto-RGD in cancer patients, J Nucl Med, 46, 1333 Vonlaufen, 2001, Integrin alpha(v)beta(3) expression in colon carcinoma correlates with survival, Mod Pathol, 14, 1126, 10.1038/modpathol.3880447 Beer, 2007, [18F]galacto-RGD positron emission tomography for imaging of alphavbeta3 expression on the neovasculature in patients with squamous cell carcinoma of the head and neck, Clin Cancer Res, 13, 6610, 10.1158/1078-0432.CCR-07-0528 Haubner, 2005, Noninvasive visualization of the activated alphavbeta3 integrin in cancer patients by positron emission tomography and [18F]Galacto-RGD, PLoS Med, 2, e70, 10.1371/journal.pmed.0020070 Washburn, 1979, 1-aminocyclobutane[11C]carboxylic acid, a potential tumor-seeking agent, J Nucl Med, 20, 1055 Shoup, 1999, Synthesis of [F-18]-1-amino-3-fluorocyclobutane-1-carboxylic acid (FACBC): a PET tracer for tumor delineation, Journal of Labelled Compounds & Radiopharmaceuticals, 42, 215, 10.1002/(SICI)1099-1344(199903)42:3<215::AID-JLCR180>3.0.CO;2-0 Shoup, 1999, Synthesis and evaluation of [F-18]1-amino-3-fluorocyclobutane-1-carboxylic acid to image brain tumors, J Nucl Med, 40, 331 McConathy, 2003, Improved synthesis of anti-[18F]FACBC: improved preparation of labeling precursor and automated radiosynthesis, Appl Radiat Isot, 58, 657, 10.1016/S0969-8043(03)00029-0 Oka, 2007, A preliminary study of anti-1-amino-3-F-18-fluorocyclobutyl-1-carboxylic acid for the detection of prostate cancer, J Nucl Med, 48, 46 Schuster, 2007, Initial experience with the radiotracer anti-1-amino-3-F-18-fluorocyclobutane-1-carboxylic acid with PET/CT in prostate carcinoma, J Nucl Med, 48, 56 Schuster, 2009, Initial experience with the radiotracer anti-1-amino-3-[F-18]fluorocyclobutane-1-carboxylic acid (anti-[F-18] FACBC) with PET in renal carcinoma, Mol Imaging Biol, 11, 434, 10.1007/s11307-009-0220-5 Holley, 1972, A unifying hypothesis concerning the nature of malignant growth, Proc Natl Acad Sci U S A, 69, 2840, 10.1073/pnas.69.10.2840 Laverman, 2002, Fluorinated amino acids for tumour imaging with positron emission tomography, Eur J Nucl Med Mol Imaging, 29, 681, 10.1007/s00259-001-0716-y Grosu, 2005, Reirradiation of recurrent high-grade gliomas using amino acid PET (SPECT)/CT/MRI image fusion to determine gross tumor volume for stereotactic fractionated radiotherapy, Int J Radiat Oncol Biol Phys, 63, 511, 10.1016/j.ijrobp.2005.01.056 Jager, 2002, Improving amino acid imaging: hungry or stuffed?, J Nucl Med, 43, 1207 McConathy, 2008, Non-natural amino acids for tumor imaging using positron emission tomography and single photon emission computed tomography, Cancer Metastasis Rev, 27, 555, 10.1007/s10555-008-9154-7 Shoup, 1999, Synthesis and evaluation of [18F]1-amino-3-fluorocyclobutane-1-carboxylic acid to image brain tumors, J Nucl Med, 40, 331 Yu, 2010, Synthesis and biological evaluation of anti-1-amino-2-[18F]fluoro-cyclobutyl-1-carboxylic acid (anti-2-[18F]FACBC) in rat 9L gliosarcoma, Bioorg Med Chem Lett, 20, 2140, 10.1016/j.bmcl.2010.02.048 Nye, 2007, Biodistribution and radiation dosimetry of the synthetic nonmetabolized amino acid analogue anti-18F-FACBC in humans, J Nucl Med, 48, 1017, 10.2967/jnumed.107.040097 Oka, 2007, A preliminary study of anti-1-amino-3-18F-fluorocyclobutyl-1-carboxylic acid for the detection of prostate cancer, J Nucl Med, 48, 46 Schuster, 2007, Initial experience with the radiotracer anti-1-amino-3-18F-fluorocyclobutane-1-carboxylic acid with PET/CT in prostate carcinoma, J Nucl Med, 48, 56 Savir-Baruch, 2010, Pilot evaluation of anti-1-amino-2-[(18)F] fluorocyclopentane-1-carboxylic acid (anti-2-[(18)F] FACPC) PET-CT in recurrent prostate carcinoma, Mol Imaging Biol Zheng, 2002, [11C]Choline as a potential PET marker for imaging of breast cancer athymic mice, Nucl Med Biol, 29, 803, 10.1016/S0969-8051(02)00339-6 Hara, 2000, Sensitive detection of mediastinal lymph node metastasis of lung cancer with 11C-choline PET, J Nucl Med, 41, 1507 Krause, 2010, [11C]Choline as pharmacodynamic marker for therapy response assessment in a prostate cancer xenograft model, Eur J Nucl Med Mol Imaging, 37, 1861, 10.1007/s00259-010-1493-2 Hara, 1997, PET imaging of brain tumor with [methyl-11C]choline, J Nucl Med, 38, 842 Parivar, 1996, Detection of locally recurrent prostate cancer after cryosurgery: evaluation by transrectal ultrasound, magnetic resonance imaging, and three-dimensional proton magnetic resonance spectroscopy, Urology, 48, 594, 10.1016/S0090-4295(96)00250-6 Yu, 2000, Imaging prostate cancer, Radiol Clin North Am, 38, 59, 10.1016/S0033-8389(05)70150-0 Kurhanewicz, 2000, The prostate: MR imaging and spectroscopy: present and future, Radiol Clin North Am, 38, 115, 10.1016/S0033-8389(05)70152-4 Nudell, 2000, Imaging for recurrent prostate cancer, Radiol Clin North Am, 38, 213, 10.1016/S0033-8389(05)70157-3 Hara, 1998, PET imaging of prostate cancer using carbon-11-choline, J Nucl Med, 39, 990 Maecke, 2005, (68)Ga-labeled peptides in tumor imaging, J Nucl Med, 46, 172S Bauwens, 2010, Optimal buffer choice of the radiosynthesis of (68)Ga-Dotatoc for clinical application, Nucl Med Commun, 31, 753, 10.1097/MNM.0b013e32833acb99 Breeman, 2005, Radiolabelling DOTA-peptides with 68Ga, Eur J Nucl Med Mol Imaging, 32, 478, 10.1007/s00259-004-1702-y Decristoforo, 2007, A fully automated synthesis for the preparation of 68Ga-labelled peptides, Nucl Med Commun, 28, 870, 10.1097/MNM.0b013e3282f1753d Zhernosekov, 2007, Processing of generator-produced 68Ga for medical application, J Nucl Med, 48, 1741, 10.2967/jnumed.107.040378 Asti, 2008, Validation of (68)Ge/(68)Ga generator processing by chemical purification for routine clinical application of (68)Ga-DOTATOC, Nucl Med Biol, 35, 721, 10.1016/j.nucmedbio.2008.04.006 Kaltsas, 2004, The diagnosis and medical management of advanced neuroendocrine tumors, Endocr Rev, 25, 458, 10.1210/er.2003-0014 Hofmann, 2001, Biokinetics and imaging with the somatostatin receptor PET radioligand (68)Ga-DOTATOC: preliminary data, Eur J Nucl Med, 28, 1751, 10.1007/s002590100639 Middendorp, 2010, Comparison of positron emission tomography with [(18)F]FDG and [(68)Ga]DOTATOC in recurrent differentiated thyroid cancer: preliminary data, Q J Nucl Med Mol Imaging, 54, 76 Ain, 1997, Somatostatin receptor subtype expression in human thyroid and thyroid carcinoma cell lines, J Clin Endocrinol Metab, 82, 1857 Rodrigues, 2005, Value of 111In-DOTA-lanreotide and 111In-DOTA-DPhe1-Tyr3-octreotide in differentiated thyroid cancer: results of in vitro binding studies and in vivo comparison with 18F-FDG PET, Eur J Nucl Med Mol Imaging, 32, 1144, 10.1007/s00259-005-1820-1 Stokkel, 2006, The value of FDG-PET in the follow-up of differentiated thyroid cancer: a review of the literature, Q J Nucl Med Mol Imaging, 50, 78 Strauss, 1991, The applications of PET in clinical oncology, J Nucl Med, 32, 623 Adams, 1998, Limited value of fluorine-18 fluorodeoxyglucose positron emission tomography for the imaging of neuroendocrine tumours, Eur J Nucl Med, 25, 79, 10.1007/s002590050197 Buchmann, 2007, Comparison of 68Ga-DOTATOC PET and 111In-DTPAOC (Octreoscan) SPECT in patients with neuroendocrine tumours, Eur J Nucl Med Mol Imaging, 34, 1617, 10.1007/s00259-007-0450-1 von Falck, 2007, Neuroendocrine tumour of the mediastinum: fusion of 18F-FDG and 68Ga-DOTATOC PET/CT datasets demonstrates different degrees of differentiation, Eur J Nucl Med Mol Imaging, 34, 812, 10.1007/s00259-006-0350-9 Koukouraki, 2006, Comparison of the pharmacokinetics of 68Ga-DOTATOC and [18F]FDG in patients with metastatic neuroendocrine tumours scheduled for 90Y-DOTATOC therapy, Eur J Nucl Med Mol Imaging, 33, 1115, 10.1007/s00259-006-0110-x Krenning, 1992, Somatostatin receptor scintigraphy with indium-111-DTPA-D-Phe-1-octreotide in man: metabolism, dosimetry and comparison with iodine-123-Tyr-3-octreotide, J Nucl Med, 33, 652 Krenning, 1993, Somatostatin receptor scintigraphy with [111In-DTPA-D-Phe1]- and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients, Eur J Nucl Med, 20, 716, 10.1007/BF00181765 Kwekkeboom, 1993, Somatostatin analogue scintigraphy in carcinoid tumours, Eur J Nucl Med, 20, 283, 10.1007/BF00169802 Dimitrakopoulou-Strauss, 2007, 68Ga-labeled bombesin studies in patients with gastrointestinal stromal tumors: comparison with 18F-FDG, J Nucl Med, 48, 1245, 10.2967/jnumed.106.038091 Gugger, 1999, Gastrin-releasing peptide receptors in non-neoplastic and neoplastic human breast, Am J Pathol, 155, 2067, 10.1016/S0002-9440(10)65525-3 Halmos, 1995, Characterization of bombesin/gastrin-releasing peptide receptors in human breast cancer and their relationship to steroid receptor expression, Cancer Res, 55, 280 Markwalder, 1999, Gastrin-releasing peptide receptors in the human prostate: relation to neoplastic transformation, Cancer Res, 59, 1152 Toi-Scott, 1996, Clinical correlates of bombesin-like peptide receptor subtype expression in human lung cancer cells, Lung Cancer, 15, 341, 10.1016/0169-5002(95)00597-8 Cuttitta, 1985, Bombesin-like peptides can function as autocrine growth factors in human small-cell lung cancer, Nature, 316, 823, 10.1038/316823a0 Mansi, 2010, Development of a potent DOTA-conjugated bombesin antagonist for targeting GRPr-positive tumours, Eur J Nucl Med Mol Imaging, 38, 97, 10.1007/s00259-010-1596-9 Mansi, 2009, Evaluation of a 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid-conjugated bombesin-based radioantagonist for the labeling with single-photon emission computed tomography, positron emission tomography, and therapeutic radionuclides, Clin Cancer Res, 15, 5240, 10.1158/1078-0432.CCR-08-3145 Liu, 2009, (68)Ga-labeled NOTA-RGD-BBN peptide for dual integrin and GRPR-targeted tumor imaging, Eur J Nucl Med Mol Imaging, 36, 1483, 10.1007/s00259-009-1123-z Jia, 2008, Linker effects on biological properties of 111In-labeled DTPA conjugates of a cyclic RGDfK dimer, Bioconjug Chem, 19, 201, 10.1021/bc7002988 Zhang, 2004, Synthesis and evaluation of bombesin derivatives on the basis of pan-bombesin peptides labeled with indium-111, lutetium-177, and yttrium-90 for targeting bombesin receptor-expressing tumors, Cancer Res, 64, 6707, 10.1158/0008-5472.CAN-03-3845 Zhang, 2007, DOTA-PESIN, a DOTA-conjugated bombesin derivative designed for the imaging and targeted radionuclide treatment of bombesin receptor-positive tumours, Eur J Nucl Med Mol Imaging, 34, 1198, 10.1007/s00259-006-0347-4 Verel, 2003, 89Zr immuno-PET: comprehensive procedures for the production of 89Zr-labeled monoclonal antibodies, J Nucl Med, 44, 1271 Holland, 2009, Standardized methods for the production of high specific-activity zirconium-89, Nucl Med Biol, 36, 729, 10.1016/j.nucmedbio.2009.05.007 Dijkers, 2009, Development and characterization of clinical-grade 89Zr-trastuzumab for HER2/neu immunoPET imaging, J Nucl Med, 50, 974, 10.2967/jnumed.108.060392 Tinianow, 2010, Site-specifically Zr-89-labeled monoclonal antibodies for ImmunoPET, Nucl Med Biol, 37, 289, 10.1016/j.nucmedbio.2009.11.010 Wadas, 2010, Coordinating radiometals of copper, gallium, indium, yttrium, and zirconium for PET and SPECT imaging of disease, Chem Rev, 110, 2858, 10.1021/cr900325h Holland, 2010, 89ZrDFO-J591 for immunoPET of prostate-specific membrane antigen expression in vivo, J Nucl Med, 51, 1293, 10.2967/jnumed.110.076174 Meijs, 1997, Zirconium-labeled monoclonal antibodies and their distribution in tumor-bearing nude mice, J Nucl Med, 38, 112 Meijs, 1996, A facile method for the labeling of proteins with zirconium isotopes, Nucl Med Biol, 23, 439, 10.1016/0969-8051(96)00020-0 Perk, 2010, p-Isothiocyanatobenzyl-desferrioxamine: a new bifunctional chelate for facile radiolabeling of monoclonal antibodies with zirconium-89 for immuno-PET imaging, Eur J Nucl Med Mol Imaging, 37, 250, 10.1007/s00259-009-1263-1 Vosjan, 2010, Conjugation and radiolabeling of monoclonal antibodies with zirconium-89 for PET imaging using the bifunctional chelate p-isothiocyanatobenzyl-desferrioxamine, Nat Protoc, 5, 739, 10.1038/nprot.2010.13 Li, 2002, In vitro and preclinical targeted alpha therapy of human prostate cancer with Bi-213 labeled J591 antibody against the prostate specific membrane antigen, Prostate Cancer Prostatic Dis, 5, 36, 10.1038/sj.pcan.4500543 Liu, 1997, Monoclonal antibodies to the extracellular domain of prostate-specific membrane antigen also react with tumor vascular endothelium, Cancer Res, 57, 3629 Liu, 1998, Constitutive and antibody-induced internalization of prostate-specific membrane antigen, Cancer Res, 58, 4055 Ruggiero, 2010, Cerenkov luminescence imaging of medical isotopes, J Nucl Med, 51, 1123, 10.2967/jnumed.110.076521 Berger, 1984, The use of Cerenkov radiation for monitoring reactions performed in minute volumes: examples from recombinant DNA technology, Anal Biochem, 136, 515, 10.1016/0003-2697(84)90254-9 Yarden, 2001, Untangling the ErbB signalling network, Nat Rev Mol Cell Biol, 2, 127, 10.1038/35052073 Hanahan, 2000, The hallmarks of cancer, Cell, 100, 57, 10.1016/S0092-8674(00)81683-9 Hynes, 2009, ErbB receptors and signaling pathways in cancer, Curr Opin Cell Biol, 21, 177, 10.1016/j.ceb.2008.12.010 Gross, 2004, Targeting the HER-kinase axis in cancer, Semin Oncol, 31, 9, 10.1053/j.seminoncol.2004.01.005 Solomayer, 2006, Comparison of HER2 status between primary tumor and disseminated tumor cells in primary breast cancer patients, Breast Cancer Res Treat, 98, 179, 10.1007/s10549-005-9147-y Wulfing, 2006, HER2-positive circulating tumor cells indicate poor clinical outcome in stage I to III breast cancer patients, Clin Cancer Res, 12, 1715, 10.1158/1078-0432.CCR-05-2087 Dijkers, 2008, Immunoscintigraphy as potential tool in the clinical evaluation of HER2/neu targeted therapy, Curr Pharm Des, 14, 3348, 10.2174/138161208786549425 Holland, 2010, Measuring the pharmacodynamic effects of a novel Hsp90 inhibitor on HER2/neu expression in mice using Zr–DFO-trastuzumab, PLoS One, 5, e8859, 10.1371/journal.pone.0008859 Dijkers, 2010, Biodistribution of 89Zr-trastuzumab and PET imaging of HER2-positive lesions in patients with metastatic breast cancer, Clin Pharmacol Ther, 87, 586, 10.1038/clpt.2010.12 Perik, 2006, Indium-111-labeled trastuzumab scintigraphy in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer, J Clin Oncol, 24, 2276, 10.1200/JCO.2005.03.8448 de Korte, 2007, 111Indium-trastuzumab visualises myocardial human epidermal growth factor receptor 2 expression shortly after anthracycline treatment but not during heart failure: a clue to uncover the mechanisms of trastuzumab-related cardiotoxicity, Eur J Cancer, 43, 2046, 10.1016/j.ejca.2007.06.024 Koehler, 2010, Iodine-124: a promising positron emitter for organic PET chemistry, Molecules, 15, 2686, 10.3390/molecules15042686 Divgi, 2007, Preoperative characterisation of clear-cell renal carcinoma using iodine-124-labelled antibody chimeric G250 (I-124-cG250) and PET in patients with renal masses: a phase I trial, Lancet Oncol, 8, 304, 10.1016/S1470-2045(07)70044-X Welch, 2003 Wykoff, 2000, Hypoxia-inducible expression of tumor-associated carbonic anhydrases, Cancer Res, 60, 7075 Loncaster, 2001, Carbonic anhydrase (CA IX) expression, a potential new intrinsic marker of hypoxia: correlations with tumor oxygen measurements and prognosis in locally advanced carcinoma of the cervix, Cancer Res, 61, 6394 Saarnio, 1998, Immunohistochemical study of colorectal tumors for expression of a novel transmembrane carbonic anhydrase, MN/CA IX, with potential value as a marker of cell proliferation, Am J Pathol, 153, 279, 10.1016/S0002-9440(10)65569-1 Vermylen, 1999, Carbonic anhydrase IX antigen differentiates between preneoplastic malignant lesions in non-small cell lung carcinoma, Eur Respir J, 14, 806, 10.1034/j.1399-3003.1999.14d14.x Uemura, 1999, MN/CA IX/G250 as a potential target for immunotherapy of renal cell carcinomas, Br J Cancer, 81, 741, 10.1038/sj.bjc.6690757 Oosterwijk, 2003, Monoclonal antibody-based therapy for renal cell carcinoma, Urol Clin North Am, 30, 623, 10.1016/S0094-0143(03)00028-4 Lawrentschuk, 2009, Investigation of hypoxia and carbonic anhydrase IX expression in a renal cell carcinoma xenograft model with oxygen tension measurements and (124)I-cG250 PET/CT, Urol Oncol Bui, 2003, Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: implications for prognosis and therapy, Clin Cancer Res, 9, 802 Lam, 2005, G250: a carbonic anhydrase IX monoclonal antibody, CurrOncol Rep, 7, 109 Steffens, 1999, Phase I radioimmunotherapy of metastatic renal cell carcinoma with 131I-labeled chimeric monoclonal antibody G250, Clin Cancer Res, 5, 3268s Brouwers, 2004, Pharmacokinetics and tumor targeting of 131I-labeled F(ab′)2 fragments of the chimeric monoclonal antibody G250: preclinical and clinical pilot studies, Cancer Biother Radiopharm, 19, 466, 10.1089/1084978041979607 Divgi, 2007, Preoperative characterisation of clear-cell renal carcinoma using iodine-124-labelled antibody chimeric G250 (124I-cG250) and PET in patients with renal masses: a phase I trial, Lancet Oncol, 8, 304, 10.1016/S1470-2045(07)70044-X Strong, 2008, A novel method to localize antibody-targeted cancer deposits intraoperatively using handheld PET beta and gamma probes, Surg Endosc, 22, 386, 10.1007/s00464-007-9611-3